The Patent Filter: How Big Pharma Runs Washington and Banned the Unpatentable

TV Advertising — The Captured Media

In 2024, the top 10 individual drugs spent a combined $2.13 billion on television advertising. The breakdown is documented by iSpot.tv and Nielsen media tracking:

Wegovy's spend is a data point worth examining in isolation: $0 in 2023 → $261.5 million in 2024. That is not advertising. That is market capture — a deliberate decision to make semaglutide culturally dominant before competitors, including compounding pharmacies offering cheaper versions, could establish a foothold.

The networks receiving this spending are the same networks that report on pharmaceutical industry practices. A 2023 Johns Hopkins study published in JAMA found that pharmaceutical companies spent 14.3% more to promote drugs with low added benefit than high-added-benefit drugs. Of 150 top-selling branded drugs reviewed, 92 were rated "low added benefit." Only 19% had a generic option available.

Political Donations and the Legislative Record

OpenSecrets data documents the donation-to-outcome pipeline with specific precision:

Vladimir Khavinson and the Soviet Peptide Project

In the early 1970s, Vladimir Khavinson was a Colonel in the Soviet military medical corps. He was approached by the Kremlin with a specific problem: how to protect nuclear submarine crews from radiation exposure, and soldiers from battlefield laser weapons. What his classified research produced — conducted over two decades under military secrecy — was a discovery about the relationship between short-chain peptides and gene expression.

Patentable vs. Unpatentable: The Decision Architecture

The Cold War Science Problem

There is a compounding factor in the Khavinson story that is worth naming directly. The research was Soviet. It was classified military research. It was conducted during the Cold War by scientists whose work Western researchers had no access to and no incentive to validate.

When the Soviet Union dissolved and the research was released, the geopolitical context remained: funding American clinical trials to validate Russian military science was not an institutional priority. The practical result: 40 years of peptide research, 15 million patients, 775 papers, and 196 patents exist in the scientific literature. It has not been replicated with Western RCT methodology. It has not been funded by anyone with financial incentive to fund it.

And in 2023, without evidence of harm, the FDA banned the key compounds from the only legal access pathway available to U.S. patients — compounding pharmacies — citing insufficient safety information. The same insufficient information that has existed since 1991.

The Access Gap: Who Loses When Unpatentable Compounds Are Banned

The practical effect of the FDA's 2023 compounding ban on BPC-157, Epithalon, TB-500, and related peptides is that the access pathway for patients who found benefit in these compounds — legal compounded prescriptions from licensed U.S. pharmacies — was eliminated. The remaining options: gray-market online sources without quality control, traveling to countries where the compounds remain legal, or paying out-of-pocket for participation in the very clinical trials that do not exist because there is no financial incentive to fund them.

This is not a hypothetical. A documented population of patients — including athletes, physicians, and individuals managing chronic inflammatory conditions — had incorporated these compounds into their medical care under physician supervision via compounding pharmacies. They were not operating outside the law. They were using a legal, regulated pathway. That pathway was closed by a regulatory decision that explicitly acknowledged insufficient safety information rather than documented harm.

The asymmetry is important: the FDA's approval pathway for new drugs requires that manufacturers demonstrate safety and efficacy — a process that costs $1-2 billion. Compounding pharmacies operate under a different framework that allows them to prepare FDA-approved APIs (active pharmaceutical ingredients) or substances on an approved list. When the FDA moves a substance to Category 2 (significant safety concerns) or Category 1 (clinical investigations necessary), compounders lose the ability to prepare it regardless of whether any harm has been documented.

The result: effective prohibition by regulatory category, achieved without evidence of harm, for compounds that have no patent holder to fund the trials that would generate the evidence needed to change the category. It is not a conspiracy. It is a documented institutional logic with documented consequences for patient access.

What Reform Would Actually Require

The structural problem in pharmaceutical regulation is not fixable through individual legislative amendments, because the problem is systemic: the regulatory apparatus was designed around a model in which private companies fund clinical trials in exchange for patent-protected market exclusivity. That model works well for generating new patentable drugs. It works very poorly for validating compounds that cannot generate the revenue needed to justify trial investment.

Several reform frameworks have been proposed and partially implemented. The NIH's National Center for Advancing Translational Sciences (NCATS) funds some trials for drugs without commercial sponsors. The European Medicines Agency has a framework for orphan drugs (rare diseases) with smaller market sizes that modify the standard approval economics. Neither addresses the specific problem of endogenous compounds — substances found naturally in the body that cannot be structurally patented.

Medicare drug price negotiation — finally authorized by the Inflation Reduction Act in 2022 after decades of industry opposition — addresses only one dimension: the price of drugs that have already completed the approval process. It does not address the upstream funding problem that determines which compounds get trials at all.

A complete reform framework would require: publicly-funded clinical trials for compounds that cannot attract private funding due to patent limitations; a regulatory pathway that distinguishes between "evidence of harm exists" and "evidence of safety has not been generated by a private funder"; and campaign finance rules that reduce the correlation between pharmaceutical donations and legislative outcomes on drug pricing and regulation. None of these are on the near-term legislative agenda in 2025.